Highlights

  • INOVIQ is prioritising a fresh operational milestone.
  • The latest update shifts attention to operating delivery.
  • Management faces financial and practical hurdles in delivering its plan.
  • Investors will track funding, deadlines and evidence of progress.

INOVIQ (ASX:IIQ) is redesigning its ovarian cancer test pathway after a failed verification study. Sample-handling differences emerged as a central problem in the review. Independent validation must come before any credible commercial rollout. For shareholders, the distinction is between a headline milestone and the harder work of translating it into durable value.

The Numbers Behind the Shift

EXO-OC had shown promise in an earlier retrospective study of 498 samples, which reported 92.5 per cent sensitivity across all stages at 98 per cent specificity. A larger study of about 1,200 samples, known as OC2200, did not repeat that result, because the company reported that many samples from several biorepositories had degraded.

Dr Mathew Moore of ResearchDx then reviewed the work. He concluded that differences in how samples were collected and handled were the largest source of variability across the five biorepositories, and that Inoviq's own analysis was accurate and reproducible.

The review also found that EXO-OC could distinguish ovarian cancer from benign gynaecological conditions within individual collection sites. That is encouraging, but it is not the same as proof across sites.

What Changes on the Ground

Inoviq plans four stages. Assay optimisation began in the third quarter of 2026, followed by verification in an independent cohort collected under a standardised protocol, then technology transfer to a US laboratory holding CAP and CLIA certification, and finally a commercial LDT launch.

The company is targeting readiness within 12 to 18 months, with laboratory validation aimed at the first half of calendar 2028. It cites an ovarian cancer diagnostics market forecast to reach US$3.1 billion by 2035, though forecasts like this are uncertain.

Cash, Capital and the Trade-Off

For the year to 30 June 2026, Inoviq reported product Revenue of A$432,047, down 21.1 per cent, and other income of A$2.18 million, including a Research and Development tax incentive accrual of A$1.78 million. The net loss after tax was A$7.51 million, or 5.69 cents per share.

Cash at 30 June 2026 was A$9.35 million. The company completed a A$10.2 million raising in November 2025 at A$0.35 a share, including A$5 million from cornerstone investor Tian An Medicare Limited.

Revenue is tiny against a loss of this size, so further funding is likely to be needed before any commercial launch. Another capital raising could dilute existing holders. Cash of A$9.35 million against that loss leaves a finite runway, though the company said reserves cover planned FY27 activities.

The Milestones That Matter

Scientific risk remains because the verification step must succeed in a fresh cohort, and the plan depends on securing good-quality samples and a laboratory partner. Regulatory treatment of an LDT is highly uncertain, and timelines in diagnostics often slip.

Next milestones to watch include progress on assay optimisation, the start of independent cohort verification, any partner announcement and the next quarterly cash-flow report. This article is general information only and is not a recommendation.